Literature DB >> 20671106

Treatment beyond progression: is it moving from belief to evidence?

Rinat Yerushalmi, Karen Gelmon.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20671106      PMCID： PMC3228025          DOI： 10.1634/theoncologist.2010-0137

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  13 in total

1.  Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

Authors:  Rupert Bartsch; Catharina Wenzel; Gabriela Altorjai; Ursula Pluschnig; Margaretha Rudas; Robert M Mader; Michael Gnant; Christoph C Zielinski; Guenther G Steger
Journal:  J Clin Oncol       Date:  2007-08-06       Impact factor: 44.544

2.  Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

Authors:  José A García-Sáenz; Miguel Martín; Javier Puente; Sara López-Tarruella; Antonio Casado; Fernando Moreno; Enrique Grande; Eduardo Díaz-Rubio
Journal:  Clin Breast Cancer       Date:  2005-10       Impact factor: 3.225

3.  Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).

Authors:  Hans-Joachim Stemmler; Steffen Kahlert; Wolfgang Siekiera; Michael Untch; Bernhard Heinrich; Volker Heinemann
Journal:  Onkologie       Date:  2005-11

4.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Authors:  Kimberly L Blackwell; Harold J Burstein; Anna Maria Storniolo; Hope Rugo; George Sledge; Maria Koehler; Catherine Ellis; Michelle Casey; Svetislava Vukelja; Joachim Bischoff; Jose Baselga; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

5.  Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.

Authors:  Filippo Montemurro; Michela Donadio; Matteo Clavarezza; Stefania Redana; Maria Elena Jacomuzzi; Giorgio Valabrega; Saverio Danese; Guido Vietti-Ramus; Antonio Durando; Marco Venturini; Massimo Aglietta
Journal:  Oncologist       Date:  2006-04

6.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Authors:  Gunter von Minckwitz; Andreas du Bois; Marcus Schmidt; Nicolai Maass; Tanja Cufer; Felix E de Jongh; Eduard Maartense; Christoph Zielinski; Manfred Kaufmann; Wolfgang Bauer; Klaus H Baumann; Michael R Clemens; Ralph Duerr; Christoph Uleer; Michael Andersson; Robert C Stein; Valentina Nekljudova; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

7.  Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories.

Authors:  Karen A Gelmon; John Mackey; Shailendra Verma; Stan Z Gertler; Nicholas Bangemann; Paul Klimo; Andreas Schneeweiss; Karl Bremer; Denis Soulieres; Katia Tonkin; Richard Bell; Bernhard Heinrich; Debjani Grenier; Reg Dias
Journal:  Clin Breast Cancer       Date:  2004-04       Impact factor: 3.225

8.  Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.

Authors:  R J Pietras; M D Pegram; R S Finn; D A Maneval; D J Slamon
Journal:  Oncogene       Date:  1998-10-29       Impact factor: 9.867

9.  Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.

Authors:  Jean-Marc Extra; Eric C Antoine; Anne Vincent-Salomon; Thierry Delozier; Pierre Kerbrat; Anne Bethune-Volters; Jean-Paul Guastalla; Marc Spielmann; Louis Mauriac; Jean-Louis Misset; Daniel Serin; Mario Campone; Christophe Hebert; Céline Remblier; Loïc Bergougnoux; Frank Campana; Moïse Namer
Journal:  Oncologist       Date:  2010-07-29

10.  Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.

Authors:  Rupert Bartsch; Catharina Wenzel; Dagmar Hussian; Ursula Pluschnig; Ursula Sevelda; Wolfgang Koestler; Gabriela Altorjai; Gottfried J Locker; Robert Mader; Christoph C Zielinski; Guenther G Steger
Journal:  BMC Cancer       Date:  2006-03-15       Impact factor: 4.430
View more
  5 in total

1.  Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities.

Authors:  Filippo Montemurro; Stefania Redana; Elena Geuna; Andrea Milani; Valentina Rossi; Rossella Martinello; Giorgio Valabrega; Massimo Aglietta
Journal:  Oncologist       Date:  2011-03-10

Review 2.  Treatment of HER2-positive breast cancer: current status and future perspectives.

Authors:  Carlos L Arteaga; Mark X Sliwkowski; C Kent Osborne; Edith A Perez; Fabio Puglisi; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2011-11-29       Impact factor: 66.675

3.  Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.

Authors:  Ariel Hammerman; Sari Greenberg-Dotan; Ilan Feldhamer; Haim Bitterman; Rinat Yerushalmi
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

4.  Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients.

Authors:  Branka Petricevic; Johannes Laengle; Josef Singer; Monika Sachet; Judit Fazekas; Guenther Steger; Rupert Bartsch; Erika Jensen-Jarolim; Michael Bergmann
Journal:  J Transl Med       Date:  2013-12-12       Impact factor: 5.531

Review 5.  New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy.

Authors:  Kevin Zarrabi; Chunhui Fang; Shenhong Wu
Journal:  J Hematol Oncol       Date:  2017-02-02       Impact factor: 17.388
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.